Myelodysplastic Syndromes

• PO (Adults ): 10 mg once daily.

Renal Impairment

• PO (Adults ): CCr 30–60 mL/min: 5 mg once daily; CCr <30 mL/min (not on dialysis): 2.5 mg once daily; CCr <30 mL/min (requiring dialysis): 2.5 mg once daily (give after dialysis on dialysis days).

Multiple Myeloma

• PO (Adults ): 25 mg once daily on days 1–21 of repeated 28-day cycles (with dexamethasone); if patients not eligible for auto-HSCT, continue treatment until disease progression or unacceptable toxicity; for patients eligible for auto-HSCT, hematopoietic stem cell mobilization should take place within 4 cycles.

Renal Impairment

• PO (Adults ): CCr 30–60 mL/min: 10 mg once daily; if patient tolerates initial dose, may ↑ to 15 mg once daily after 2 cycles; CCr <30 mL/min (not on dialysis): 15 mg every 48 hr; CCr <30 mL/min (requiring dialysis): 5 mg once daily (give after dialysis on dialysis days).

Maintenance Therapy for Multiple Myeloma Following Autologous Hematopoietic Stem Cell Transplantation

• PO (Adults ): After adequate hematologic recovery (ANC ≥ 1000/mcL and/or platelet counts ≥75,000/mcL), initiate therapy with 10 mg once daily continuously on Days 1–28 of repeated 28–day cycles); after 3 cycles, dose may be ↑ to 15 mg once daily, if tolerated; continue treatment until disease progression or unacceptable toxicity.

Renal Impairment

• PO (Adults ): CCr 30–60 mL/min: 5 mg once daily; CCr <30 mL/min (not on dialysis): 2.5 mg once daily; CCr <30 mL/min (requiring dialysis): 2.5 mg once daily (give after dialysis on dialysis days).

Mantle Cell Lymphoma

• PO (Adults ): 25 mg once daily on days 1–21 of repeated 28–day cycles; continue treatment until disease relapse or unacceptable toxicity develops.

Renal Impairment

• PO (Adults ): CCr 30–60 mL/min: 10 mg once daily; CCr <30 mL/min (not on dialysis): 15 mg every 48 hr; CCr <30 mL/min (requiring dialysis): 5 mg once daily (give after dialysis on dialysis days).

Follicular Lymphoma or Marginal Zone Lymphoma

• PO (Adults ): 20 mg once daily on days 1–21 of repeated 28–day cycles for up to 12 cycles (with rituximab).

Renal Impairment

• PO (Adults ): CCr 30–60 mL/min: 10 mg once daily; if patient tolerates initial dose, may ↑ to 15 mg once daily after 2 cycles; CCr <30 mL/min (not on dialysis): 5 mg once daily; CCr <30 mL/min (requiring dialysis): 5 mg once daily (give after dialysis on dialysis days).